Please login to the form below

Not currently logged in
Email:
Password:

BMS expand biologics manufacturing deal with Lonza

Will make wider use of New Hampshire facilities ahead of product launch
Lonza building

Bristol-Myers Squibb and Lonza have entered a multi-year expansion of their existing biologics manufacturing agreement.

The contract expansion will include the production of commercial quantities of a second BMS biologic medicine at Lonza's manufacturing facility in Portsmouth, New Hampshire.

Lou Schmukler, president of global manufacturing and supply at BMS, said: “Our expanded relationship with Lonza is an important example of our global manufacturing strategy to meet anticipated demand for our commercial biologics portfolio and prepare to bring our late-stage clinical assets to patients by supplementing our in-house manufacturing capabilities.”

BMS and Lonza have been collaborating since 2003 to produce commercial supplies of biologics medicine marketed by BMS worldwide. Lonza currently also produces supplies of an investigational biologics medicine for BMS.

Marc Funk, COO of Lonza's pharma and biotech sector, said: “We are pleased to extend our relationship with BMS for the commercial production of their innovative drug substance.

“This reinforces Lonza's mission to support life-saving medicines by being a reliable supplier of drug substance for our customers with high-quality commercial GMP manufacturing services delivered to the market.”

The agreement, which covers BMS' biologic specialty care portfolio and pipeline, will see the pharma company make wider use of Lonza's development and manufacturing facilities.

Article by
Kirstie Pickering

3rd November 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics